Although the numbers in this subgroup are small and the study retrospective, this observation is concordant with previous data showing that ER−/HER2+ cancers, on average, have greater HER2 amplification/expression and a greater dependency on HER2 signalling [29]. This evidence concerns the gene ERBB2 and cancer.